Published in
Elsevier, Lancet Haematology, 12(6), p. e616-e629, 2019
DOI: 10.1016/s2352-3026(19)30167-x
Links
Tools
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Journal article published in 2019 by
Graham H. Jackson,
Faith E. Davies,
Charlotte Pawlyn,
David A. Cairns,
Alina Striha,
Corinne Collett,
Anna Waterhouse,
John R. Jones,
Bhuvan Kishore,
Mamta Garg,
Cathy D. Williams,
Kamaraj Karunanithi 
,
Jindriska Lindsay,
Jamie N. Wilson,
Matthew W. Jenner
and other authors.
,
Jindriska Lindsay,
Jamie N. Wilson,
Matthew W. Jenner
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 